SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

OLIVEIRA, L. P. M. et al. Possible molecular mechanisms soy-mediated in preventing and treating nonalcoholic fatty liver disease. Nutr. Hosp. [online]. 2012, vol.27, n.4, pp.991-998. ISSN 0212-1611.

    1. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 (Suppl. 1): S34-S38. [ Links ]

    2. Chaia K, V, Lopes RE, Rosa G, Morais Oliveira EM, Kimi US, Lima DC et al. Influence of fat diet in glicidic metabolism in obese women with Pro12Pro genotype in PPARgamma2 gene. Nutr Hosp 2010; 25 (4): 622-9. [ Links ]

    3. De Luis DA, Aller R, Izaola O, Gonzalez SM, Conde R. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 2010; 25 (5): 730-5. [ Links ]

    4. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38 (2): 413-9. [ Links ]

    5. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A et al. Dietary fat content modifies liver fat in over-weight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90(5): 2804-9. [ Links ]

    6. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24 (2):248-54. [ Links ]

    7. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38 (8): 705-9. [ Links ]

    8. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (4): 865-73. [ Links ]

    9. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis 2010; 9: 42. [ Links ]

    10. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15 (3): 310-5. [ Links ]

    11. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22 (3): 293-303. [ Links ]

    12. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104 (4): 861-7. [ Links ]

    13. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92 (9): 3490-7. [ Links ]

    14. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51 (5): 1593-602. [ Links ]

    15. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118 (3): 829-38. [ Links ]

    16. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005; 54 (7): 987-93. [ Links ]

    17. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412 (15-16): 1297-305. [ Links ]

    18. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008; 48 (3): 399-406. [ Links ]

    19. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28 (1): 27-38. [ Links ]

    20. Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F et al. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007; 52 (8): 2006-14. [ Links ]

    21. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115 (5): 1343-51. [ Links ]

    22. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114 (4): 842-5. [ Links ]

    23. Vanni E, Bugianesi E, Kotronen A, De MS, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42 (5): 320-30. [ Links ]

    24. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52 (5): 1836-46. [ Links ]

    25. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54 (7): 1003-8. [ Links ]

    26. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 2006; 41 (5): 462-9. [ Links ]

    27. Camma C, Bruno S, Di M, V, Di BD, Rumi M, Vinci M et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43 (1): 64-71. [ Links ]

    28. Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008; 14 (16): 2474-86. [ Links ]

    29. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7 (2): 85-96. [ Links ]

    30. Romero-Gómez M. Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Revista Española de Enfermedades Digestivas 2006; 98 (8): 605-615. [ Links ]

    31. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59 (10): 1410-5. [ Links ]

    32. Younossi ZM, Baranova A, Ziegler K, Del GL, Schlauch K, Born TL et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42 (3):665-74. [ Links ]

    33. Pettinelli P, Obregon AM, Videla LA. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp 2011; 26 (3): 441-50. [ Links ]

    34. Yessoufou A, Wahli W. Multifaceted roles of peroxisome pro-liferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 2010; 140: w13071. [ Links ]

    35. Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 2007; 68 (2): 72-82. [ Links ]

    36. Fon TK, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids 2011; 2011:783976. [ Links ]

    37. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006; 55 (8): 2159-70. [ Links ]

    38. Simmen FA, Mercado CP, Zavacki AM, Huang SA, Greenway AD, Kang P et al. Soy protein diet alters expression of hepatic genes regulating fatty acid and thyroid hormone metabolism in the male rat. J Nutr Biochem 2010; 21 (11): 1106-13. [ Links ]

    39. Takahashi Y, Ide T. Effects of soy protein and isoflavone on hepatic fatty acid synthesis and oxidation and mRNA expression of uncoupling proteins and peroxisome proliferator-activated receptor gamma in adipose tissues of rats. J Nutr Biochem 2008; 19 (10): 682-93. [ Links ]

    40. Torre-Villalvazo I, Tovar AR, Ramos-Barragan VE, Cerbon-Cervantes MA, Torres N. Soy protein ameliorates metabolic abnormalities in liver and adipose tissue of rats fed a high fat diet. J Nutr 2008; 138 (3): 462-8. [ Links ]

    41. Astley SB. An introduction to nutrigenomics developments and trends. Genes Nutr 2007; 2 (1): 11-3. [ Links ]

    42. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275 (37): 28918-28. [ Links ]

    43. Shapiro H, Tehilla M, ttal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011; 30 (1): 6-19. [ Links ]

    44. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86 (2): 285-300. [ Links ]

    45. Chang JH, Kim MS, Kim TW, Lee SS. Effects of soybean supplementation on blood glucose, plasma lipid levels, and erythrocyte antioxidant enzyme activity in type 2 diabetes mellitus patients. Nutr Res Pract 2008; 2 (3): 152-7. [ Links ]

    46. Noriega-López L, Tovar AR, González-Granillo M, Hernández-Pando R, Escalante B, Santillan-Doherty P et al. Pancreatic insulin secretion in rats fed a soy protein high fat diet depends on the interaction between the amino acid pattern and isoflavones. J Biol Chem 2007; 282 (28): 20657-66. [ Links ]

    47. Pipe EA, Gobert CP, Capes SE, Darlington GA, Lampe JW, Duncan AM. Soy protein reduces serum LDL cholesterol and the LDL cholesterol:HDL cholesterol and apolipoprotein B:apolipoprotein A-I ratios in adults with type 2 diabetes. J Nutr 2009; 139 (9): 1700-6. [ Links ]

    48. Ronis MJ, Chen Y, Badeaux J, Badger TM. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr 2009; 139 (8): 1431-8. [ Links ]

    49. Tovar AR, Torre-Villalvazo I, Ochoa M, Elias AL, Ortiz V, Guilar-Salinas CA et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005; 46 (9): 1823-32. [ Links ]

    50. Badger TM, Ronis MJ, Wolff G, Stanley S, Ferguson M, Shankar K et al. Soy protein isolate reduces hepatosteatosis in yellow Avy/a mice without altering coat color phenotype. Exp Biol Med (Maywood) 2008; 233 (10): 1242-54. [ Links ]

    51. Shukla A, Brandsch C, Bettzieche A, Hirche F, Stangl GI, Eder K. Isoflavone-poor soy protein alters the lipid metabolism of rats by SREBP-mediated down-regulation of hepatic genes. J Nutr Biochem 2007; 18 (5): 313-21. [ Links ]

    52. Ascencio C, Torres N, Isoard-Acosta F, Gómez-Perez FJ, Hernández-Pando R, Tovar AR. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 2004; 134 (3): 522-9. [ Links ]

    53. Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002; 25 (10): 1709-14. [ Links ]

    54. Gudbrandsen OA, Wergedahl H, Berge RK. A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats. Nutrition 2009; 25 (5): 574-80. [ Links ]

    55. Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS et al. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Nutrition 2011; 27 (9): 943-948. [ Links ]

    56. Gudbrandsen OA, Wergedahl H, Mork S, Liaset B, Espe M, Berge RK. Dietary soya protein concentrate enriched with iso-flavones reduced fatty liver, increased hepatic fatty acid oxidation and decreased the hepatic mRNA level of VLDL receptor in obese Zucker rats. Br J Nutr 2006; 96 (2): 249-57. [ Links ]

    57. Shim JY, Kim KO, Seo BH, Lee HS. Soybean isoflavone extract improves glucose tolerance and raises the survival rate in streptozotocin-induced diabetic rats. Nutr Res Pract 2007; 1(4): 266-72. [ Links ]